Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study

View ORCID ProfileGiuseppe Gritti, Federico Raimondi, Diego Ripamonti, Ivano Riva, Francesco Landi, Leonardo Alborghetti, Marco Frigeni, Marianna Damiani, Caterina Micò, Stefano Fagiuoli, Roberto Cosentini, Ferdinando Luca Lorini, Lucia Gandini, Luca Novelli, Jonathan P Morgan, Benjamin M J Owens, Karan J K Kanhai, Gordana Tonkovic Reljanovic, Marco Rizzi, Fabiano Di Marco, View ORCID ProfileAlessandro Rambaldi
doi: https://doi.org/10.1101/2020.04.01.20048561
Giuseppe Gritti
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Giuseppe Gritti
  • For correspondence: g.gritti@asst-pg23.it
Federico Raimondi
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diego Ripamonti
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivano Riva
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Landi
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonardo Alborghetti
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Frigeni
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianna Damiani
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caterina Micò
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Fagiuoli
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Cosentini
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ferdinando Luca Lorini
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucia Gandini
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luca Novelli
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan P Morgan
2EUSA Pharma, Hemel Hempstead, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin M J Owens
2EUSA Pharma, Hemel Hempstead, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karan J K Kanhai
2EUSA Pharma, Hemel Hempstead, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordana Tonkovic Reljanovic
3ErgoMed PLC Guildford, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Rizzi
1Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabiano Di Marco
4University of Milan, Milan, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandro Rambaldi
4University of Milan, Milan, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alessandro Rambaldi
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Severe COVID-19 is characterised by interstitial pneumonia and hyperinflammation, with elevated levels of pro-inflammatory cytokines, such as IL-6. Effective treatments are urgently needed, and IL-6 is a rational target to reduce hyperinflammation.

Methods An observational, control cohort, single-centre study initiated at the Papa Giovanni XXIII Hospital in Bergamo, Italy included patients with COVID-19 confirmed by a nasopharyngeal swab positive for severe acute respiratory syndrome coronavirus 2 RNA and interstitial pneumonia requiring ventilatory support. Patients were treated with either best supportive care and siltuximab or best supportive care alone. Propensity score matching was applied to minimise differences in baseline covariates between patient cohorts. The main outcome was mortality in siltuximab-treated patients compared with patients in the matched-control cohort. This study (Siltuximab in Severe COVID-19, SISCO) is registered with ClinicalTrials.gov, identifier NCT04322188.

Findings Thirty patients received siltuximab, while 188 control patients received only best supportive care. Siltuximab-treated patients were matched to 30 control patients using the propensity score analysis of baseline covariates. The 30-day mortality rate was significantly lower in the siltuximab-treated than the matched-control cohort patients (HR 0·462, 95% CI 0·221– 0·965); p=0·0399). The mean follow-up was 33·3 days (range 7–58 days) for the siltuximab-treated patients and 22·8 days (range 2–45 days) for the control cohort. Sixteen siltuximab-treated patients were discharged from hospital, four remained on mechanical ventilation, and 10 patients died.

Interpretation Patients with rapidly progressing COVID-19 respiratory failure requiring ventilatory support may benefit from treatment with siltuximab to reduce mortality and cytokine-driven hyperinflammation associated with severe disease. These findings require validation in a randomised controlled clinical trial.

Funding Papa Giovanni XXIII Hospital and the Italian Association for Cancer Research funded the study. EUSA Pharma supplied siltuximab, and provided funding for data collection, analysis, and development of the publication.

Competing Interest Statement

Declaration of interests Jonathan P Morgan, Benjamin MJ Owens and Karan JK Kanhai are employees of EUSA Pharma. Alessandro Rambaldi reports consultancy fees from Amgen, Novartis, Pfizer, Celgene, Italfarmaco, Gilead, Roche and Omeros, travel support from Amgen, Novartis, Celgene, Italfarmaco, Gilead and Roche, and research grants from Amgen, Italfarmaco and Roche, outside the submitted work. Caterina Mico reports travel support from Medac, outside the submitted work. Diego Ripamonti reports personal fees from Gilead, Janssen and ViiV, outside the submitted work. Fabiano Di Marco reports grants from Boehringer Ingelheim, GSK, Novartis and AZ, and personal fees from Boehringer Ingelheim, GSK, Chiesi, Zambon, Novartis, Guidotti/Malesci, AZ, Menarini, Mundipharma, TEVA and Almiral, outside the submitted work. Guiseppe Gritti reports non-financial support from Gilead Kite, Roche, Takeda and Janssen, and personal fees from Gilead Kite, Autolus, Roche, IQvia, Takeda, Amgen and Italfarmaco, outside the submitted work. Ivano Riva reports travel support from Aferetica outside the submitted work. Stefano Fagiuoli reports grants from Gilead and Novartis and personal fees from Gilead, Abbvie, MSD, Novartis, Bayer, Astellas, Kedrion, and Intercept, outside the submitted work. All other authors declare no competing interests.

Clinical Trial

NCT04322188

Funding Statement

Papa Giovanni XXIII Hospital and the Italian Association for Cancer Research funded the study. EUSA Pharma supplied siltuximab, and provided funding for data collection, analysis, and development of the publication.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data will be made available upon reasonable requests submitted to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted June 20, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study
Giuseppe Gritti, Federico Raimondi, Diego Ripamonti, Ivano Riva, Francesco Landi, Leonardo Alborghetti, Marco Frigeni, Marianna Damiani, Caterina Micò, Stefano Fagiuoli, Roberto Cosentini, Ferdinando Luca Lorini, Lucia Gandini, Luca Novelli, Jonathan P Morgan, Benjamin M J Owens, Karan J K Kanhai, Gordana Tonkovic Reljanovic, Marco Rizzi, Fabiano Di Marco, Alessandro Rambaldi
medRxiv 2020.04.01.20048561; doi: https://doi.org/10.1101/2020.04.01.20048561
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study
Giuseppe Gritti, Federico Raimondi, Diego Ripamonti, Ivano Riva, Francesco Landi, Leonardo Alborghetti, Marco Frigeni, Marianna Damiani, Caterina Micò, Stefano Fagiuoli, Roberto Cosentini, Ferdinando Luca Lorini, Lucia Gandini, Luca Novelli, Jonathan P Morgan, Benjamin M J Owens, Karan J K Kanhai, Gordana Tonkovic Reljanovic, Marco Rizzi, Fabiano Di Marco, Alessandro Rambaldi
medRxiv 2020.04.01.20048561; doi: https://doi.org/10.1101/2020.04.01.20048561

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Respiratory Medicine
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (139)
  • Cardiovascular Medicine (1947)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (699)
  • Epidemiology (11102)
  • Forensic Medicine (8)
  • Gastroenterology (624)
  • Genetic and Genomic Medicine (3168)
  • Geriatric Medicine (308)
  • Health Economics (561)
  • Health Informatics (2042)
  • Health Policy (863)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12720)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2986)
  • Nursing (164)
  • Nutrition (463)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1552)
  • Ophthalmology (477)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (912)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2785)
  • Public and Global Health (5591)
  • Radiology and Imaging (1094)
  • Rehabilitation Medicine and Physical Therapy (635)
  • Respiratory Medicine (760)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)